Stay updated on CABozantinib in NSCLC MET Clinical Trial

Sign up to get notified when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CABozantinib in NSCLC MET Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision stamp updated from v3.5.3 to v3.5.4, indicating a newer page version is now live. This reflects a minor update to the page rather than a substantive change to study details.
    Difference
    0.0%
    Check dated 2026-05-14T23:06:24.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    The page shows a new Revision: v3.5.3 label, replacing the previous v3.5.2. This reflects a minor platform update and does not alter the study data or its presentation.
    Difference
    0.0%
    Check dated 2026-04-30T17:31:32.000Z thumbnail image
  4. Check
    27 days ago
    No Change Detected
  5. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.5.2 was added and v3.5.0 was removed. This maintenance update does not modify study content.
    Difference
    0.0%
    Check dated 2026-04-16T10:16:18.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    Padova, PD, Italy 35128 has been added and Padua, PD, Italy 35128 removed from the locations list.
    Difference
    0.0%
    Check dated 2026-04-09T07:55:15.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-25T19:52:06.000Z thumbnail image
  8. Check
    70 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-11T14:37:41.000Z thumbnail image

Stay in the know with updates to CABozantinib in NSCLC MET Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CABozantinib in NSCLC MET Clinical Trial page.